New Study on BRCA Mutation in Women with Ovarian Cancer
A new study of 1,001 women with ovarian cancer found that 14% of them carried a BRCA1 or BRCA2 mutation. However, 44% of those women did not have a family history of breast or ovarian cancer. The BRCA...
View ArticleDrugs Approved Faster in US, Cost More
According to a study by the Tufts Center for the Study of Drug Development, more cancer drugs were approved in the US than in the EU during the 2010-2011 time period. However, these drugs cost more in...
View ArticleFasting Before Chemotherapy?
There is a growing body of data indicating that fasting before chemotherapy renders cancer cells more sensitive to the toxic effects of those drugs. On the other side of the coin, some drugs are more...
View ArticleWhen Less Is More – Editorial
The L.A. Times published an editorial July 29 summing up years of data showing that aggressively screening and treating people for cancer does not always benefit them. The editorial also points out...
View ArticleTaxane Therapy Does Not Affect Pregnancy
A small retrospective study of women receiving taxane therapy for breast or ovarian cancer while pregnancy showed no statistically significant outcomes in maternal or fetal health. Read the abstract...
View ArticleDose Dense Therapy Appears Beneficial
A study of 637 Japanese women with ovarian, fallopian or primary peritoneal cancer showed that dose dense chemotherapy provided a benefit. The standard of care arm provided chemotherapy every three...
View ArticleFertility Sparing Surgery Recommended by Study
A study of 240 patients with ovarian cancer concluded that young women with early stage disease be provided the option of fertility sparing surgery, rather than aggressive debulking. The study found...
View ArticleNew Guidelines on Palliative Care Released
The National Comprehensive Cancer Network (NCCN) released new guidelines on palliative care for cancer patients. “The guidelines outline procedures for screening, assessment, palliative care...
View ArticleEU Approves Avastin in Combination Therapy for Recurrent Ovarian Cancer
The European Commission approved the use of Avastin with Gemzar and Carboplatin for treatment of the first recurrence of ovarian cancer. See the article here The post EU Approves Avastin in Combination...
View ArticleEU Reviews Folate Receptor Drug
The European Union will review vintafolide, a folate receptor drug for ovarian cancer, made by Endocyte/Merck. The regulatory agency should make a decision in the first half of 2013. Read an article on...
View Article
